Investment Analysts’ Weekly Ratings Changes for Sol-Gel Technologies (SLGL)

Sol-Gel Technologies (NASDAQ: SLGL) recently received a number of ratings updates from brokerages and research firms:

• 10/19/2026 – Sol-Gel Technologies had its “buy” rating reaffirmed by HC Wainwright. They now have a $110.00 price target on the stock.
• 10/15/2026 – Sol-Gel Technologies was upgraded by Zacks Research from “hold” to “strong-buy”.
• 10/14/2026 – Sol-Gel Technologies is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 10/6/2026 – Sol-Gel Technologies had its “buy” rating reaffirmed by HC Wainwright.
• 9/1/2026 – Sol-Gel Technologies had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity at Sol-Gel Technologies

In other news, major shareholder Opaleye Management Inc. bought 35,113 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were purchased at an average price of $69.32 per share, with a total value of $2,434,033.16. Following the completion of the acquisition, the insider directly owned 520,000 shares in the company, valued at approximately $36,046,400. This trade represents a 7.24% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have purchased a total of 53,430 shares of company stock worth $3,684,739 in the last quarter. 66.51% of the stock is owned by company insiders.

Sol-Gel Technologies Ltd. is a dermatology-focused specialty pharmaceutical company based in Israel. The company develops and commercializes topical prescription medicines for common skin conditions, using proprietary delivery technologies designed to improve the stability, tolerability, and effectiveness of active pharmaceutical ingredients.

Its marketed products include Epsolay, a topical benzoyl peroxide cream indicated for the treatment of inflammatory lesions associated with rosacea, and Twyneo, a fixed-dose topical combination of tretinoin and benzoyl peroxide for acne vulgaris.